Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
Addition of Immunotherapy in Lung Cancer The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 16, 2018
|
| In: |
The New England journal of medicine
Year: 2018, Volume: 378, Issue: 22, Pages: 2078-2092 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1801005 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1056/NEJMoa1801005
|
| Author Notes: | L. Gandhi, D. Rodríguez‑Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M.J. Hochmair, S.F. Powell, S.Y.-S. Cheng, H.G. Bischoff, N. Peled, F. Grossi, R.R. Jennens, M. Reck, R. Hui, E.B. Garon, M. Boyer, B. Rubio‑Viqueira, S. Novello, T. Kurata, J.E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M.C. Pietanza, and M.C. Garassino, for the KEYNOTE-189 Investigators |
| Summary: | Addition of Immunotherapy in Lung Cancer The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone. Immune-related adverse effects were more common with the combination. |
|---|---|
| Item Description: | Gesehen am 13.12.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMoa1801005 |